#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Bilastine in the treatment of allergic rhinitis – meta-analysis shows advantage of lower somnolence

A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine in the treatment of allergic rhinitis (AR), which includes symptoms of common rhinitis and allergic sensitization upon allergen exposure. The disease causes significant discomfort for patients and reduces their quality of life, which is why its control is essential for their daily functioning.
Source: Allergic Reactions 24. 5. 2022

News Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level

Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes, but according to current findings, these measures fail for a significant portion of study participants. In the Diabetes Prevention Program (DPP) study, one in five patients in the lifestyle intervention group developed type 2 diabetes within 4 years. However, there are individuals with prediabetes who do not develop diabetes without lifestyle intervention even after 11 years of follow-up. This indicates the need to create more precisely stratified intervention strategies based on the identification of high-risk (HR) and low-risk (LR) individuals with prediabetes. This is precisely the focus of a recently published study by German authors.
Source: Modern Treatment of Diabetes 2. 11. 2022

News Safety of Tofacitinib in Ulcerative Colitis – Combined Results of 6 Studies

At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in Vancouver, Canada, the results of the final safety analysis of tofacitinib in the treatment of ulcerative colitis from a clinical trial program involving 1,157 patients with exposure duration to this therapy of up to 9.2 years were presented.
Source: Intestinal Inflammations 7. 12. 2023

News Sport and Programmed Sports Therapy in Hemophiliacs

Sport and physical activity are increasingly becoming an integrated part of the treatment plan for hemophiliacs. It was not long ago that sports were almost forbidden for these patients. The possibilities for active movement were determined by the availability of effective treatment. It has also become clear that sport is not just sport but to some extent also part of the treatment – thanks to the care of experienced physiotherapists.
Source: Hemophilia with Movement 2. 9. 2020

News The Benefit of Dabigatran Over Warfarin Is Greater in Patients with Atrial Fibrillation and Diabetes Than in Nondiabetics

As early as 2015, an analysis of the results of the RE-LY study in patients with atrial fibrillation showed that the reduction in absolute risk of embolic events with dabigatran compared to warfarin is greater in patients with diabetes than in those without diabetes.
Source: Anticoagulant Treatment 24. 4. 2020

Journal articles Predictors of combined hormone contraception choice between Czech and Slovak women

Author of the article: Tomáš Fait Source: Česká gynekologie | 3/2011 11. 7. 2011

News Successful Long-Term Subcutaneous Prophylaxis of Hereditary Angioedema – Case Study

Hereditary angioedema (HAE), arising from a deficiency of C1 inhibitor (C1-INH), clinically manifests as swelling of the subcutaneous tissue and mucous membranes. The standard prophylactic therapy consists of intravenous (i.v.) substitution of C1-INH. We present a case study of successful long-term subcutaneous (s.c.) prophylaxis in a patient who had to discontinue i.v. prophylaxis.
Source: Hereditary Angioedema 8. 12. 2022

News Participation in sports activities, frequency and severity of sports injuries in children with hemophilia

Children with hemophilia used to be discouraged from engaging in sports activities due to the potential increased risk of bleeding. The introduction of prophylaxis into routine practice has improved the possibility for children to participate in various sports activities. A study conducted by Dutch authors evaluated the involvement of boys with hemophilia in sports activities and their potential link with sports injuries and bleeding.
Source: Hemophilia with Movement 28. 3. 2022

News Sport Therapy as Part of Hemophilia Management

A study by authors from the University of Wuppertal in Germany specifically examined the impact of a half-year programmed sport therapy on the subjective physical performance and quality of life of individuals with hemophilia.
Source: Hemophilia with Movement 27. 10. 2020

News Can identifying alpha-1 antitrypsin deficiency before liver transplantation extend survival?

Alpha-1 antitrypsin deficiency (AATD) can manifest (among other things) as liver cirrhosis. The study presented below examined the survival of patients diagnosed with AATD before and after liver transplantation.
Source: Deficiency of Alpha-1-Antitrypsin 1. 7. 2021

News How do Hemodialysis Patients Perceive the Coronavirus Pandemic? Survey Results

Hemodialysis patients are at higher risk of SARS-CoV-2 infection due to repeated visits to medical facilities. Additionally, these are often older and comorbid patients living in nursing homes. This study, presented below, examines how these patients perceived anti-epidemic measures during the first wave of the pandemic and how this extraordinary situation impacted their mental state.
Source: Chronic Kidney Disease 26. 1. 2021

News Shared Decision-Making on Kidney Function Replacement

Peritoneal dialysis (PD) is not a new development, but its significance is becoming increasingly recognized. Until recently, we may not have fully appreciated its value, but in light of the global threat posed by the current pandemic, its importance is starkly clear. PD is an accessible solution designed for home care and allows patients to avoid visits to healthcare facilities to some extent.
Source: Chronic Kidney Disease 30. 11. 2020

News Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?

There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), which were developed as antihyperglycemic drugs for the treatment of type 2 diabetes. These antidiabetic medications are recommended for patients with heart or renal disease or at high risk of these complications. However, is it worthwhile to consider their use in diabetics as part of long-term primary cardiorenal prevention? Israeli authors sought the answer to this question.
Source: Diabetes 14. 11. 2022

News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds

A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.
Source: Wound Healing 4. 8. 2022

News Impact of Tofacitinib on the Quality of Life of Patients with Ulcerative Colitis

Tofacitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of certain rheumatic diseases and ulcerative colitis (UC). The work presented at this year's 18th congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen, Denmark, focused on its impact on the quality of life in terms of physical and mental functions in patients with UC.
Source: Intestinal Inflammations 7. 12. 2023

News Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A

With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and emicizumab in terms of cost-effectiveness were presented at a recently held ASH conference.
Source: Hemophilia 15. 1. 2020

News Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice

Based on real-world data from the USA, a recently published study compared two recombinant human factor VIII (rFVIII) products with extended half-life (EHL) – efmoroctocog alfa and rurioctocog alfa pegol, in terms of dosing frequency, weekly consumption, and dose variability.
Source: Hemophilia 11. 4. 2023

News Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility

Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory diseases. According to available evidence, its mechanism of action is complex, encompassing not only a mucolytic effect but also antioxidant and antibacterial properties. Two clinical studies evaluated changes in respiratory distress parameters and quality of life in patients using this medication in the early period after discharge from a healthcare facility where they were hospitalized due to severe COVID-19.
Source: Cough Therapy 28. 2. 2022

News Prevention and Treatment of Thromboembolism in the Elderly

Despite advances in the prevention and treatment of venous thromboembolism, morbidity and mortality associated with this condition remain high in certain risk groups. An international expert group focused on the elderly in its analysis published in the Thrombosis Journal.
Source: Thromboprophylaxis 9. 6. 2022

News Modern View on Schizophrenia Therapy Through the Lens of Lurasidone

At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia Diagnosis', which took place on October 18, 2021, in Prague, Professor of Psychiatry and Molecular Biology Christoph U. Correll from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell spoke. His lecture included insights on current approaches to schizophrenia therapy and key information on one of the newest antipsychotics - lurasidone.
Source: Modern Treatment of Schizophrenia 14. 12. 2021

News Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A

Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.
Source: Hemophilia 20. 2. 2023

Journal articles Hereditary angioedema in gravidity

Author of the article: MUDr. Barbora Kuřecová, MUDr. Petr Janků, prof. MUDr. Jiří Litzman, CSc. Source: Praktická gynekologie | 2/2006 13. 4. 2006

News Pharmacokinetics and Safety of Bilastine 10 mg in Children Aged 6–11 Years

The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria from the age of 6 years. Recently, results from two post hoc analyses on the pharmacokinetics and safety of bilastine in children aged 6–11 years have been published.
Source: Allergic Reactions 17. 8. 2020

News Administration of Erdosteine After Severe Course of COVID-19 in the Early Period After Patient Discharge From Medical Facility

Erdosteine is a mucomodulatory drug used in the therapy of various acute and chronic respiratory diseases. Its mechanism of action is considered complex based on available evidence, encompassing antioxidant and antibacterial effects along with its mucolytic effect. Two clinical studies assessed changes in respiratory distress parameters and quality of life in patients taking this medication in the early period after discharge from medical facilities where they were hospitalized for severe COVID-19 (respiratory failure, pneumonia).
Source: Cough Therapy 8. 4. 2022

News Maintenance of Remission with Tofacitinib in Patients with UC – Results of the OCTAVE Open Study

Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication include oral administration and predictable kinetics. The long-term efficacy of tofacitinib was studied in the OCTAVE Open study.
Source: Intestinal Inflammations 28. 5. 2022

1 6 7 8 9 10 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#